Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 8, 2026

Back to the front page

From X

@aleabitoreddit

Serenity on X

$AAOI has finished a $500m ATM In April.. $600m ATM in June. Then filed another $600m in August. It's out of my control if management wants to abuse this trash repeated ATM structure. Instead following $AXTI like LTA prepayments and using that to fund buildout. Or taking private placements like $NVDA + Nebius for $2B and using that to fund buildout. Or convertible notes at 40% premiums. It's really hard for the stock to break out of $100 or $150 or $200 if there's $600M of selling pressure at those levels (and maybe expectations of future ATMs). I had the same criticism with $IREN with their $6B ATM, which is why it's been rangebound for half a year. And I'll say the same thing with my own thesis names too. I see $AAOI operationally very bullish for 2027, with $471m/month transceiver revenue. 400k ELSFP units/month entering 2028. The revenue ramp is absurd and can compress to single digit forward P/E. But I find it hard to get excited over funding infinite ATMs during the buildout, when you're sacrificing opportunity cost with names currently profitable like $SNDK or Samsung. I think a lot of retail investors conflate stock performance with how a company is doing operationally. $AAOI is capitalizing on a bottleneck with high demand visibility, but stock has been going nowhere near-term with repeated ATMs. I do expect AOI to strongly outperform (especially in 2027) if they stop issuing these stupid ATMs.
@aleabitoreddit

Serenity on X

I would have a much more favorable view on $IREN after they finish their $6B ATM in terms of stock performance (I think they're like 41.5% through). I think Mirantis acqusition would materially shift a lot of perception of how they rank relative to $CRWV, $NBIS, Lambda, Tensorwave, and others in terms of cluster performance once they finish integration. I've always started software side of things is actually a moat (backing up what Coreweave CEO was saying), which was what $IREN lacked before. But M&A to get that gap fixed is probably the most bullish part of what they've done.
@aleabitoreddit

Serenity on X

Wow $NBIS relative outperformance is wild. Back in 2025 I wrote my Neocloud thesis on $IREN to $CRWV. But I made the decision months later to consolidate it all into Nebius... Despite the the hate from FinX back then. Very interesting to see Nebius up 6% even during sector drop… After Oracle was reportedly seeking payment protection if Project Jupiter misses its 2028 opening. With Oracle: "seeking to protect itself from potential cost increases related to a large DC ​project in New Mexico by sending a force majeure notice" per Reuters. Lot of new people like to piggyback after it’s up a lot, but there was a lot less people bullish back in 2025. Especially during the period with a ton of institutional short sellers back in December. I still think markets might be underestimating sum of parts growth, even if its core business grows like crazy 2027+ onwards.

Investor Letters

All letters
MTMTY · short

Metlen Energy & Metals PLC

Metlen Energy & Metals faces a 40% short case centered on its overpriced aluminium, alumina and Greek power businesses.

MTMTY $6.8B
Value Investors Club

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

MDA $4.2B
Aurelion Research 4 clicks

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

CURB $3.6B
Real Assets, Real Value 5 clicks

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…

STVN $3.6B
Best Anchor Stocks 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 75 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.